Cargando…
Challenges in severe asthma: Do we need new drugs or new biomarkers?
Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biol...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550875/ https://www.ncbi.nlm.nih.gov/pubmed/36237537 http://dx.doi.org/10.3389/fmed.2022.921967 |
_version_ | 1784805980823879680 |
---|---|
author | Adatia, Adil Vliagoftis, Harissios |
author_facet | Adatia, Adil Vliagoftis, Harissios |
author_sort | Adatia, Adil |
collection | PubMed |
description | Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future. |
format | Online Article Text |
id | pubmed-9550875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95508752022-10-12 Challenges in severe asthma: Do we need new drugs or new biomarkers? Adatia, Adil Vliagoftis, Harissios Front Med (Lausanne) Medicine Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future. Frontiers Media S.A. 2022-09-27 /pmc/articles/PMC9550875/ /pubmed/36237537 http://dx.doi.org/10.3389/fmed.2022.921967 Text en Copyright © 2022 Adatia and Vliagoftis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Adatia, Adil Vliagoftis, Harissios Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title_full | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title_fullStr | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title_full_unstemmed | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title_short | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
title_sort | challenges in severe asthma: do we need new drugs or new biomarkers? |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550875/ https://www.ncbi.nlm.nih.gov/pubmed/36237537 http://dx.doi.org/10.3389/fmed.2022.921967 |
work_keys_str_mv | AT adatiaadil challengesinsevereasthmadoweneednewdrugsornewbiomarkers AT vliagoftisharissios challengesinsevereasthmadoweneednewdrugsornewbiomarkers |